Athersys Sees Efficacy Sign In MultiStem Phase I Safety Study In Heart Attack
This article was originally published in Pharmaceutical Approvals Monthly
Heart attack patients treated with Athersys' adult stem cell product MultiStem during a Phase I safety study showed improvement in cardiac function, a surprise early efficacy signal that has the company headed into Phase II studies with a spring in its step
You may also be interested in...
As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.
Following the deal news, Athersys' stock price soared during same-day trading.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011